Forecasting The Future: 9 Analyst Projections For Capricor Therapeutics
Portfolio Pulse from Benzinga Insights
Capricor Therapeutics (NASDAQ:CAPR) has been evaluated by 9 analysts over the past three months, with a majority holding bullish views. The average 12-month price target has increased by 21.4% to $26.44. Analysts have maintained or raised their ratings, reflecting positive sentiment. Despite positive revenue growth, the company faces challenges with low ROE and ROA.
October 09, 2024 | 7:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Capricor Therapeutics has received predominantly bullish analyst ratings, with an average price target increase of 21.4% to $26.44. Analysts have maintained or raised their ratings, indicating positive sentiment. However, the company faces challenges with low ROE and ROA despite positive revenue growth.
The majority of analysts have a bullish outlook on CAPR, with a significant increase in the average price target. This suggests a positive short-term impact on the stock price. However, financial metrics like ROE and ROA indicate underlying challenges, which may temper the overall positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100